CBO projects Senate drug pricing bill would cut the development of 10 drugs over 30 years
“The reason the number is smaller is that the package has changed over time,” Rachel Sachs, a law professor at Washington University in St. Louis told Endpoints News. “The negotiation provisions now not only apply to fewer drugs, but they are formally limited in that they only begin after a drug has been on the market for a certain amount of time. So companies have a period of time during which negotiation is not present. CBO likely considered that, as well.”